{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:03:34Z","timestamp":1790892214145,"version":"4.1.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>The programmed death-1 (PD-1) pathway of immune evasion is exploited by many malignancies to limit host T-cell-mediated immune responses. Nivolumab is a PD-1-blocking monoclonal antibody that disrupts this pathway and is FDA approved for the treatment of metastatic melanoma, renal cell carcinoma, and squamous non\u2013small cell lung cancer. In this case report, we describe the first published pediatric experience of nivolumab in refractory classic Hodgkin lymphoma. In this patient with primary refractory disease and high disease burden, cytokine release syndrome requiring inotropic support developed following the first infusion of nivolumab. The patient subsequently demonstrated a dramatic clinical response with resolution of fevers, transfusion independence, improvement in functional status, and very good partial response on PET\/CT following a single dose. Nivolumab was continued with corticosteroid and antihistamine premedication without further adverse events and clinical benefit was sustained at 11 months after therapy initiation, despite evidence of slow radiographic disease progression.<\/jats:p>","DOI":"10.1097\/mph.0000000000000703","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T10:47:21Z","timestamp":1478861241000},"page":"e263-e266","source":"Crossref","is-referenced-by-count":38,"title":["Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma"],"prefix":"10.1097","volume":"39","author":[{"given":"Alexandra E.","family":"Foran","sequence":"first","affiliation":[{"name":"Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen R.","family":"Nadel","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna F.","family":"Lee","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, British Columbia Cancer Agency"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Deyell","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology\/Bone Marrow Transplantation, British Columbia Children\u2019s Hospital"},{"name":"Michael Cuccione Childhood Cancer Research Program, Child & Family Research Institute, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pcl.2014.09.010","article-title":"Pediatric lymphomas and histiocytic disorders of childhood","volume":"62","author":"Allen","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.critrevonc.2012.07.002","article-title":"Hodgkin lymphoma","volume":"85","author":"Gobbi","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"e0124614","DOI":"10.1371\/journal.pone.0124614","article-title":"A multi-component model of Hodgkin\u2019s lymphoma","volume":"10","author":"Staege","year":"2015","journal-title":"PLoS One"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"spec feature","key":"R6-20230918","first-page":"180","article-title":"Opdivo (nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"R8-20230918","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood.V126.23.583.583","article-title":"Nivolumab in patients (pts) with relapsed or refractory classical Hodgkin lymphoma (R\/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039)","volume":"126","author":"Ansell","year":"2015","journal-title":"Blood"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V126.23.584.584","article-title":"PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: safety, efficacy, and biomarker assessment","volume":"126","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/ejh.12396","article-title":"Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature","volume":"94","author":"Alig","year":"2015","journal-title":"Eur J Haematol"},{"key":"R14-20230918","first-page":"134","article-title":"Rituximab and cytokine release syndrome","volume":"5","author":"Kulkarni","year":"2012","journal-title":"Case Rep"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome [Erratum appears in Blood. 2015 Aug 20;126(8):1048. Note: dosage error in article text]","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201707000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:11:37Z","timestamp":1695010297000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201707000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000703","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}